The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | SYMPATICO: efficacy and safety of ibrutinib plus venetoclax in treatment-naive MCL
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the treatment-naive cohort in the SYMPATICO clinical trial (NCT03112174), a multi-center study that investigated the efficacy of a combination of ibrutinib and venetoclax in mantle cell lymphoma (MCL). Prof. Wang highlights the trial’s impressive results, making this combination therapy is particularly beneficial for older patients with comorbidities who may not be suitable candidates for chemotherapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, this morning, just a few hours ago, I presented the SYMPATICO clinical trial. The SYMPATICO clinical trial is an international multi-center clinical trial that has two cohorts. The first cohort was randomized in the relapse setting. I have presented them earlier. At this meeting at ASCO, I presented the second cohort, which is the treatment-naive cohort. The treatment-naive cohort was treated with ibrutinib-venetoclax...
Yes, this morning, just a few hours ago, I presented the SYMPATICO clinical trial. The SYMPATICO clinical trial is an international multi-center clinical trial that has two cohorts. The first cohort was randomized in the relapse setting. I have presented them earlier. At this meeting at ASCO, I presented the second cohort, which is the treatment-naive cohort. The treatment-naive cohort was treated with ibrutinib-venetoclax. We showed a very high response rate of 95% and CR rate was very high as well at 69%. The median PFS was 40.2 months. You can see that the follow-up time is long on this trial data and also the response was very high and was also durable. I really think this is an addition of the two agents. These two agents are both oral drugs in the front line. So it is especially good for the older people who had many comorbidities who were not able to get chemotherapy. So this chemo-free double oral therapy is a very good option for the older patient with the mantle cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
